Cyclophosphamide
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Zhejiang University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07240857CT.gov A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer | — | Enrolling By Invitation | — | — | — |
NCT07641049CT.gov Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT07244393CT.gov Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07090369CT.gov Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT06236139CT.gov Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06228404CT.gov Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | — | Active Not Recruiting | — | — | — |
NCT05766371CT.gov Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06344715CT.gov Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | — | Unknown | — | — | — |
NCT05256381CT.gov A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04471974CT.gov ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
Show 15 more trialsShow fewer
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04090528CT.gov pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03873805CT.gov PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04060342CT.gov GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | — | Terminated | — | — | — |
NCT03861403CT.gov A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03805594CT.gov 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03582475CT.gov Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | — | Active Not Recruiting | — | — | — |
NCT03419442CT.gov Multi-academic Center Study of Xofigo Patients | — | Completed | — | — | — |
NCT03506997CT.gov Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT03406858CT.gov Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03514836CT.gov A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03473925CT.gov Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | — | Completed | — | — | — |
NCT03248570CT.gov Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | — | Completed | — | — | — |
NCT02312557CT.gov Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | — | Active Not Recruiting | — | — | — |
NCT02095717CT.gov Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Zhejiang University | P2 | BB · 66 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
| Abiraterone | AstraZeneca | P4 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →